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Objectives. Serum cystatin C seems to be an accurate marker of glomerular filtration rate (GFR) compared to serum creatinine.
The aim of this work was to explore the possibility of using serum cystatin C instead of serum creatinine to early predict renal
failure in cancer patients who received platinum based chemotherapy. Design and Methods. Serum creatinine, serum cystatin
C concentrations, and GFR were determined simultaneously in 52 cancer patients received carboplatin-based or cisplatin-based
chemotherapy. Serum creatinine was assayed on Cobas C6000-Roche, serum cystatin C assay was performed on AIA 360-Tosoh,
and GFR was determined in all patients, before the first cycle of chemotherapy and before the subsequent administrations. Results.
In the overall series, for the prediction of a fall of GFR < 80mL/min/1.73m2, the AUC of the ROC curve for cystatin C was 0,667
and the best threshold was 1.135mg/L (sensitivity 90.5%, specificity 61.1%). For a GFR fall < 60mL/min/1.73m2, the AUC of ROC
curve for cystatin C was 74.3% and the best threshold was 1.415mg/L (sensitivity 66.7%, specificity 73.2%). Conclusions. Baseline
cystatin C values were not able to predict renal failure during subsequent treatment. In conclusion, serum cystatin C is not a reliable
early marker to efficiently predict renal failure in patients receiving chemotherapy.
1. Introduction
During the treatment with chemotherapeutic agents such as
cisplatin or carboplatin renal function should be closelymon-
itored, to predict the potential renal damage [1]. Nephrotoxi-
city of these cytotoxic agents is dose-related and cumulative;
therefore, early recognition of renal damage is needed, in
order to use them in a safe and effective way [2].
The glomerular filtration rate (GFR) provides the best
overall estimate of renal function. It is calculated with
the clearance of an exogenous substance such as inulin,
iothalamate, Cr-EDTA. However, because of the cost and
inconvenience, serum creatinine and creatinine clearance
(CrCl) are the most widely used measures of renal function.
CrCl, however, tends to overestimate GFR because creatinine
is filtered by the glomeruli and secreted by the tubules,
and furthermore it implies the need for a 24-hour urine
collection that is obviously inconvenient for the patient and
susceptible of errors [3, 4]. To make the serum creatinine-
based GFR measurements more simple, some formulae such
as Cockcroft-Gault have been introduced [5]. Some have
reported the utility of GFR equation based on creatinine
for use in oncology patients during chemotherapy treatment
[6, 7].
Cystatin C, a cysteine protein kinase inhibitor, is con-
stituted of 120 amino acids and belongs to the cystatin
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superfamily. It is filtrated by the glomeruli and almost
completely reabsorbed and catabolized in the proximal renal
tubular cells. This protein is not significantly influenced
by inflammation and, differently from creatinine, it is not
affected by muscle mass, sex, race, and height. In addition,
creatinine assay suffers from analytical influences [8].
Several studies have shown that cystatin C is a more
sensitive marker of decreased GFR than serum creatinine
[9–11], but in several malignancies, the serum cystatin C
levels are increased probably related to its nature as a cysteine
protease inhibitor [12].
In this study we tested the predictive accuracy of the
baseline serum cystatin C levels as a tool to predict the
occurrence of renal failure, defined as two different levels
of GFR impairment, in patients receiving platinum-based
chemotherapy. We also tested whether baseline cystatin C
levels could predict time to renal failure in these patients.
2. Materials and Methods
2.1. Patients. Patients affected by either lung, urologic, or
gynecologic tumors, for whom a treatment with platinum-
based chemotherapy, containing cisplatin or carboplatin,
was indicated as eligible, were included in this study. The
only specific exclusion criteria was a baseline creatinine
value over the reference interval. Therefore, before treatment
start, all the patients were screened for renal impairment
by creatinine measurement, and patients with pretreatment
renal impairment were excluded from the study.
2.2. Study. In all patients we measured serum cystatin C,
creatinine concentrations, and calculated glomerular filtra-
tion rate (GFR) according to Cockcroft-Gault equation (the
most commonly used when our study began) at baseline,
before each cycle, and at the end of the last cycle according to
clinical practice. For the present analysis, only baseline values
of cystatin C were used.
2.3. Analytical Methods. Serum samples were taken in Vacu-
tainer tube SST II Advance (BD, ref. 366468) and analyzed in
less than one hour.
The serum cystatin C concentration was determined by
Fluorimetric Enzyme Immuno Assay (FEIA) on AIA 360,
Tosoh Bioscience, Tokyo, Japan. The cystatin C reference
range was 0.52–0.97mg/L.
The serum creatinine concentration was determined
enzymatically by a spectrophotometric method on a Cobas
C6000 automated analyzer, Roche Diagnostics. The creati-
nine reference ranges were 0.51–0.95mg/dL for females and
0.67–1.17 for males.
GFR was calculated by Cockcroft-Gault equation
GFR [mL/min/1.73m2] = 175 × [serum creatinine (mg/
dL)]−1.154 × (Age)−0.203 × 𝑅.
The Cockcroft-Gault equation was used to guide carbo-
platin dosing.
2.4. Statistical Analysis. Statistical analysis was performed
using S-PLUS software (S-PLUS 6.0 Professional, release 1;
Insightful Corporation, Seattle,WA, USA) and SPSS software
(SPSS Statistics, version 2; IBM).
In detail, to assess the predictive role of baseline cystatin
C for subsequent renal failure, we used the cystatin C concen-
tration measured before the first cycle of chemotherapy and
we exploratively considered two different definitions of renal
failure based on the values of GFR: below 60mL/min/1.73m2
or 80mL/min/1.73m2 during the treatment.
To assess the predictive accuracy of serum cystatin C
concentration in predicting renal failure (reduction of GFR)
we performed ROC curves. For each ROC curve (GFR
< 60mL/min/1.73m2 and GFR < 80mL/min/1.73m2) the
area under the curve (AUC) and the best threshold were
identified, describing sensitivity and specificity. In detail,
best threshold was calculated as the value with the highest
Youden’s index J (sensitivity + specificity − 1).
As a reference, the same analyses were performed using
baseline creatinine levels.
For both definitions of renal failure (GFR < 60mL/min/
1.73m2 and GFR < 80mL/min/1.73m2), patients were divid-
ed into 2 groups according to the baseline value of cystatin C
(higher or lower than the best threshold) and Kaplan Meier
curves were employed to evaluate the time to renal failure in
the two groups.
3. Results
3.1. Patients Clinic Features. A total of 52 patients (17men and
35women)were included in the study.Themedian agewas 62
years (range 41–78). Of these patients, 36 had urogynecologic
cancers and 16 had lung cancer. According to the standard
chemotherapy regimens used in clinical practice for the
different tumors, 27 patients were treated with cisplatin and
25 with carboplatin (Table 1).
Prior to first chemotherapy administration, the median
serum creatinine level was 0.72 (range 0.51–1.14), the median
serum cystatin C level was 1.30 (range 0.75–1.94), and the
median of CrCl calculated by the Cockcroft-Gault equation
was 94.3 (range 47.0–143).
At the end of treatment the median serum creatinine
level was 0.73 (0.46–1.72), the median serum cystatin C level
was 1.27 (0.61–2.14) and the median creatinine clearance
calculated by the Cockcroft-Gault equation was 93.2 (29.4–
146) (Table 2).
3.2. Roc Curves. The ROC analysis demonstrated a better
predictive performance for creatinine compared to cystatin
C (Figures 1–4).
When considering GFR < 80mL/min/1.73m2 during the
treatment for the definition of renal failure, AUC for cystatin
C was 0.667, while the AUC for creatinine was higher (0.792).
The best threshold value for cystatin C was 1.135 (associated
with 90.5% sensitivity and 41.1% specificity, Youden index
0.319).
When considering GFR < 60mL/min/1.73m2 during the
treatment for the definition of renal failure, AUC for cystatin
C was 0.743, while the AUC for creatinine was 0.818. The
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Table 1: Patients characteristics.
Characteristic Nr. of patients (%)
Total 52 (100)
Male 17 (32.7)
Female 35 (67.3)
Median age, range 62, 41–78
Tumor type
Lung cancer 16 (30.8)
Urogynecological cancer 36 (69.2)
Chemotherapy
Cisplatin 27 (51.9)
Cisplatin + gemcitabine 17 (32.7)
Cisplatin + vinorelbine 7 (13.5)
Cisplatin + Alimta 3 (5.8)
Carboplatin 25 (48.1)
Carboplatin + gemcitabine 4 (7.7)
Carboplatin + taxol 20 (38.5)
Impaired renal function at the
beginning of the therapy
GFR < 80 17 (32.7)
GFR < 60 6 (11.5)
Table 2: Renal function markers values.
Parameter Measured value
Median Range
Serum creatinine, mg/dL (n)
Before chemotherapy (53) 0.72 0.51–1.14
At the end of the cycle (53) 0.73 0.46–1.72
Serum cystatin C, mg/L
Before chemotherapy (51) 1.30 0.75–1.94
At the end of the cycle (46) 1.27 0.61–2.14
GFR, mL/min/1,73m2
Before chemotherapy (53) 94.3 47.0–143
At the end of the cycle (53) 93.2 29.4–146
best threshold value for cystatin C was 1.415 (associated with
66.7% sensitivity and 73.2% specificity, Youden index 0.398).
3.3. Description of Time to Renal Failure. Description of time
to renal failure was performed using both definitions of renal
failure (GFR < 80mL/min/1.73m2 and GFR < 60mL/min/
1.73m2).
When renal failure was defined as GFR < 80mL/min/
1.73m2, the best threshold of baseline cystatin C value
according to Youden index (1.135) allowed dividing patients
with baseline GFR > 80mL into two groups. Seventeen
patients had GFR < 80mL at baseline and were excluded;
therefore the number of patients included in this analysis was
35. Among them, a fall of GFR < 80mL was observed in 8
cases. Time to GFR < 80mL was not significantly different
between the two groups (Figure 5).
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Figure 1: Cystatin C ROC curve for the prediction of renal failure
(defined as GFR < 80mL/min/1.73m2).
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Figure 2: Creatinine ROC curve for the prediction of renal failure
(defined as GFR < 80mL/min/1.73m2).
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Figure 3: Cystatin C ROC curve for the prediction of renal failure
(defined as GFR < 60mL/min/1.73m2).
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Figure 4: Creatinine ROC curve for the diagnosis of renal failure
(defined as GFR < 60mL/min/1.73m2).
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Figure 5: KaplanMeier curve for the evaluation of the time to renal
failure (defined as GFR < 80mL/min/1.73m2). Only patients with
baseline GFR ≥ 80mL/min/1.73m2 were included in the analysis.
Blue curve: patients with baseline Cystatin C < 1.135. Green curve:
patients with baseline Cystatin C ≥ 1.135.
When renal failure was defined as GFR < 60mL/min/
1.73m2, the best threshold of baseline cystatinC value accord-
ing to Youden index (1.415) allowed to dividing patients with
baseline GFR > 60 into two groups. Six patients had GFR <
60mL at baseline and were excluded; therefore the number
of patients included in this analysis was 46. Among them, a
fall of GFR < 60mL was observed during the treatment in
only 6 cases. Time to GFR < 60 was not significantly different
between the two groups (Figure 6).
4. Discussion
For the calculation of adequate doses of nephrotoxic agents
like cisplatin and carboplatin, estimation of kidney function
in each patient is required. The evaluation of the glomerular
filtration rate (GFR) by exogenousmarkers is a gold standard;
however it is complex, expensive, and difficult in routine
clinical practice. Therefore, GFR calculation methods are
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Figure 6: KaplanMeier curve for the evaluation of the time to renal
failure (defined as GFR < 60mL/min/1.73m2). Only patients with
baseline GFR ≥ 60mL/min/1.73m2 were included in the analysis.
Blue curve: patients with baseline Cystatin C < 1.415. Green curve:
patients with baseline Cystatin C ≥ 1.415.
mostly based on the creatinine serum level. The Cockcroft-
Gault creatinine-based equation is widely applied.
Recent studies suggest that serum cystatin Cmay serve as
a reliable alternative clinical marker of renal function [13, 14].
Our results indicate that, in cancer patients receiving
platinum-based chemotherapy, baseline cystatin C serum
level does not predict renal failure.
There are some limitations to our analysis. First, we used a
small study population, including lung and urogynecological
cancers (with the exclusion of renal cancer). On one side,
this might limit generalization of our findings although we
believe that the drug combinations used in this study cover
a large amount of the use of platinum derivatives in clinical
practice. On the other side, heterogeneity of the underlying
type of cancer might be a confounding factor, although it
should improve generalizability of our findings, partially
contrasting limitations deriving from the small sample size.
Second, we did not adjust our analysis for comorbidity and
concomitant medications. However, it should be considered
that our patients were all considered eligible for an active
anticancer treatment based on a platinum-containing com-
bination, limiting the scenario of possible comorbidity or
concomitant treatments to the ones that do not prevent
the prescription of chemotherapy in clinical practice. Third,
we did not use the CKD-EPI equation for calculation of
GFR values, now considered as a gold standard method.
Actually, our choice was due to the fact that, at the time
this study was conducted, the Cockroft-Gault formula was
routinely used in our practice (and in many clinical trials).
While we are aware that the performance of the Cockroft
Gault equation differs from that of CKD-EPI for GFR values
higher than 90mL/min, we underline that the choice of the
formula should not represent a bias of this analysis because
the same formula was applied for baseline and subsequent
assessments of GFR. Fourth, our analysis does not account
for dynamic change of cystatin C levels. Our choice was due
to the consideration that an analysis of the change of cystatin
Analytical Cellular Pathology 5
over the treatment might be confused with the outcome.
In principle, if cystatin was a good biomarker, its change
during treatment would be parallel to the reduction of renal
function and the analysis would be biased in favour of finding
a statistically significant association. For these reasons, we
focused on predictive ability of the baseline values only that
could be useful in clinical decision making. Finally, our
analysis, due to the small number of patients and to the very
limited number of renal failures during the chemotherapy,
showed a fair statistical power to detect the predictive ability
of baseline cystatin C values. As detailed in the results, only
6 events were recorded when considering the threshold of
60mL/min/1.73m2 for the definition of renal failure and
only 8 events when considering the higher threshold of
80mL/min/1.73m2. In other words, our results, showing no
difference in the time to renal failure between groups of
patients divided according to baseline value of cystatin C,
do not support the predictive role of cystatin C but cannot
definitely rule out the potential usefulness of this test. Given
that, even with cisplatin or other drugs usually considered at
relevant risk of renal toxicity, the absolute number of renal
impairment occurring during the treatment is reasonably
limited, only studies with a very large number of patients
would have enough power to demonstrate the predictive role
of this (or other) biomarkers.
Furthermore, in several malignancies, the serum cystatin
C levels are elevated, probably related to its nature as a
cysteine protease inhibitor [15] and this phenomenon is
associated with more aggressive forms of tumors [16]. Our
data are consistent with those from other studies reporting
the serum cystatin C levels increase in cancer patients. In fact
patients that received platinum based chemotherapy do not
seem to result from impaired kidney function [13, 17].
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